Dishman Pharmaceuticals and Chemicals, a global outsourcing partner for the pharma industry, has entered strategic alliance with Codexis, Inc, a California based biotechnology company. Under this alliance, Dishman will use Codexis' proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and API's for innovator pharmaceutical companies. Further, the companies will work exclusively on certain select accounts.
Codexis offers a wide selection of enzymes for the pharmaceutical synthesis of chiral compounds. With the majority of today's drugs containing at least one chiral centre, this this technology is directed at the very heart of pharmaceutical manufacture. In comparison to traditional chemical synthesis, this technology offers a number of significant advantages like cost reduction compared with conventional complex transformations as result of telescoped processes, significant reduction in environmental impact through reduce use of organic solvents and reduced energy process.
According the Dishman official, this alliance will benefit Codexis and its customers by enabling Codexis to offer production of both intermediates and final APIs in Dishman's world-class manufacturing asset base. We are delighted to be working with Codexis on this innovative technology. It adds another dimension to the already extensive portfolio of services offered by the Dishman Group. Our customers will benefit from cheaper, cleaner, greener processes manufactured in a low cost environment, a significant differentiator given today's regulatory and market conditions.